NASDAQ$LPSN

LivePerson Inc · Q2 2023 earnings

Q2 2023 earnings · · Investor relations

Briefing

Reported total revenue of $97.5M and adjusted EBITDA of $12.8M, exceeding guidance.

LivePerson's Q2 2023 financial results showed a total revenue of $97.5 million, which was above the midpoint of their guidance range. The company's adjusted EBITDA was $12.8 million, exceeding the top end of their guidance range. LivePerson signed 69 deals in total, consisting of 33 new and 36 existing customer contracts, including 3 seven-figure deals.

  • Total revenue was $97.5 million, exceeding the midpoint of prior guidance.
  • Adjusted EBITDA was $12.8 million, above the top end of guidance.
  • Signed 69 deals in total, including 33 new and 36 existing customer contracts.
  • Trailing-twelve-months average revenue per enterprise and mid-market customer increased 14% to $575,000.

Headline financials

Total Revenue

$97.5M

Previous: $133M-26.4%
EPS (adj)

$0.12

Previous: -$0.23+152.2%
Adjusted EBITDA

$12.8M

Previous: -$5.5M+332.7%
Capital Expenditures

$7.37M

Previous: -$25.2M+129.3%
Free Cash Flow

-$32M

Previous: -$101M+68.2%
Net Income

$10.8M

Previous: -$75.4M+114.4%
Operating Income

$5.64M

Previous: -$70.2M+108.0%
Gross Profit

$66.6M

Previous: $87.5M-23.9%
Cash & Equivalents

$214M

Previous: $426M-49.8%
Total Assets

$898M

Previous: $1.15B-22.2%
Stock-Based Comp

-$18.1M

Previous: $36.5M-149.7%

Revenue & EPS history

LivePerson · Revenue · Quarterly

$97.5M

Q2 2023-26.4%vs Q2 2022
Beat estimate in 12 of 14 quarters(86%)
ActualEstimate

Revenue by segment

LivePerson · $97.5M total across 2 segments · Q2 2023

  • Hosted services
    $81.3M
  • Professional services
    $16.2M

Forward guidance

For the third quarter, LivePerson expects total revenue to range from $97 million to $101 million and adjusted EBITDA to range from $5.9 million to $12.9 million. For full year 2023, LivePerson is narrowing the revenue guidance range to $388 million - $400 million and increasing the adjusted EBITDA guidance range to $19 million - $32 million.

Tailwinds

  • Maintaining the midpoint of full year 2023 revenue guidance at $394M.
  • Narrowing the full year 2023 revenue guidance range to $388M - $400M.
  • Increasing the full year 2023 Adjusted EBITDA guidance range to $19M - $32M.
  • Expecting B2B Core recurring revenue to represent 86% of total revenue for full year 2023.
  • Expecting strong growth from WildHealth's core business.

Headwinds

  • Third quarter revenue is expected to range from $97M - $101M.
  • B2B Core recurring revenue is expected to represent 85% of total revenue in Q3 due to a one-time increase in non-core revenue.
  • Third quarter adjusted EBITDA is expected to range from $5.9M - $12.9M.
  • Full year 2023 revenue growth (year-over-year) is expected to be (19)% - (16)%.
  • Full year 2023 Adjusted EBITDA margin is expected to be 4.9% - 8.0%.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q2 2023

Historical avgQ2 2023

-1.7%

Avg return

Earnings day

-1.7%

Avg return

5 days after

-3.3%

Avg return

30 days after

35%

22 / 62 earnings

Positive

+43.3%

Q1 2020

Best reaction

-56.4%

Q4 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-5.6%-20.1%
Q4 2025-1.1%-1.5%+1.9%
Q3 2025+12.4%-2.9%+1.3%
Q1 2025+8.1%+12.8%+0.0%
Q4 2024-16.0%-22.7%-38.2%
Q3 2024-25.7%-27.4%-23.1%
Q2 2024-11.6%-10.9%-4.7%
Q1 2024-2.0%+11.9%+10.2%
Q4 2023-50.6%-51.0%-61.1%
Q3 2023-9.0%-7.7%+15.0%
Q2 2023+18.2%+26.4%-1.2%
Q1 2023+27.9%+0.7%-17.4%
Q4 2022-56.4%-60.1%-44.1%
Q3 2022+20.4%+34.7%+12.0%
Q2 2022-17.8%-11.1%-26.5%
Q1 2022-5.4%-6.3%-14.1%
Q4 2021-20.7%+3.0%+4.7%
Q3 2021-5.3%-6.7%-32.3%
Q2 2021-2.5%-3.3%+3.7%
Q1 2021-3.1%-3.5%+1.2%
Q4 2020+9.1%+7.6%-13.5%
Q3 2020-5.5%-3.8%+2.4%
Q2 2020+24.0%+27.1%+17.6%
Q1 2020+43.3%+44.5%+47.6%
Q4 2019-23.3%-26.3%-53.3%
Q3 2019-16.3%-16.1%-9.8%
Q2 2019+3.6%-1.7%+21.9%
Q1 2019-0.8%-0.7%-3.2%
Q4 2018+4.3%+8.9%+7.4%
Q3 2018-7.5%-11.0%-16.7%
Q2 2018+3.9%+3.9%+15.9%
Q1 2018+8.4%+9.3%+17.5%
Q4 2017+15.3%+14.5%+21.3%
Q3 2017-17.9%-16.4%-21.4%
Q2 2017+17.9%+18.3%+11.8%
Q1 2017+22.6%+27.7%+41.5%
Q4 2016-0.7%+4.3%-4.3%
Q3 2016-3.0%+1.2%+0.0%
Q2 2016-15.0%-11.3%+4.4%
Q1 2016-3.5%
Q4 2015-18.8%
Q3 2015-7.9%
Q2 2015+12.3%
Q1 2015-10.3%
Q4 2014-1.1%
Q3 2014+0.7%
Q2 2014+21.8%
Q1 2014-3.0%
Q4 2013-8.0%
Q3 2013+20.8%
Q2 2013+0.7%
Q4 2012-6.1%
Q3 2012-12.5%
Q1 2011+7.7%
Q1 2012+2.1%
Q4 2011-0.4%
Q4 2009-0.4%
Q3 2010-4.2%
Q3 2011-4.2%
Q2 2010-3.5%
Q4 2010-3.5%
Q2 2011-3.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro